TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05956314

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics Assessments
Description: Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics Assessments
Description: Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2.
Study: NCT05425446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study: NCT06797973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sodium Chloride Injection, 0.9%)
Description: 0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.
Study: NCT06799065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-295
Description: ATX-295 Tablets will be taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-295
Description: ATX-295 Tablets will be taken orally
Study: NCT06799182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: Based on the results of the dental examination and the diagnosis of the periodontal tissue condition according to the new classification of periodontal disease, we performed appropriate non-surgical treatment of periodontal disease, provided oral hygiene instruction, and took a biofilm sample from the deep periodontal pocket. We then collected a sample of the altered mucosa during bowel surgery for colorectal cancer and conducted a microbiological investigation using quantitative culture to compare the presence of Fusobacterium nucleatum and Porphyromonas gingivalis in the pariodontal pocket and altered intestinal mucosa.
Study: NCT06799520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: VIS171 will be administered as a SC injection.
Study: NCT06799260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester (KME)
Description: 500 mg/kg body weight of the KME supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester (KME)
Description: 500 mg/kg body weight of the KME supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester (KME)
Description: 500 mg/kg body weight of the KME supplement
Study: NCT05425446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study: NCT06799260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester (KME)
Description: 500 mg/kg body weight of the KME supplement
Study: NCT05425446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study: NCT06799260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taste-matched placebo drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taste-matched placebo drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taste-matched placebo drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taste-matched placebo drink

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: iTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: iTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS
Description: cTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS
Description: cTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
Study: NCT06799481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participate in personalized, progressive aerobic training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive active lifestyle behavior coaching

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up
Description: Receive calls from the trainer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to Physitrack

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participating in strength training exercises
Study: NCT06799741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1 100 mg
Description: human monoclonal antibody (mAb) intravenous solution~or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1 100 mg
Description: human monoclonal antibody (mAb) intravenous solution~or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1 300 mg
Description: human monoclonal antibody (mAb) intravenous solution~or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1 300 mg
Description: human monoclonal antibody (mAb) intravenous solution~or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1 900 mg
Description: human monoclonal antibody (mAb) intravenous solution~or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1 900 mg
Description: human monoclonal antibody (mAb) intravenous solution~or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (0.9% saline intravenous solution) 12:2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (0.9% saline intravenous solution) 12:2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (0.9% saline intravenous solution) 12:2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (0.9% saline intravenous solution) 12:2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (0.9% saline intravenous solution) 12:2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (0.9% saline intravenous solution) 12:2
Study: NCT06799013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 ug HDT 321
Description: HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25ug HDT-321
Description: HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50ug HDT-321
Description: HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50ug HDT-321
Description: HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
Study: NCT06800014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Participants in the telerehabilitation group will receive weekly home exercise instructions through a mobile application installed on their or their caregivers' smartphones, in addition to their standard rehabilitation program. These instructions will include videos, reminders, and directives for the exercises, with compliance monitored through mini-surveys delivered via the app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise
Description: Participants in the conventional exercise group will continue their standard rehabilitation program supplemented with printed home exercise instructions, including visuals and text, similar to the content provided to the TG.
Study: NCT06798818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-rapid therapeutic hypothermia induction by total liquid ventilation
Description: Vent2Cool System is a targeted temperature management device used to induce ultra-rapid therapeutic hypothermia by total liquid ventilation.
Study: NCT06797895

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VR assisted mobility
Description: Commercially-based VR experience used to help move upper extremities to music, similar to dancing or Tai-Chi.
Study: NCT06800118

Intervention type: DEVICE
Intervention: Music intervention
Description: Music will be played for patients undergoing coronary angiography, and vasospasm and pain levels will be evaluated.
Study: NCT06798636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 5 mg with cognitive behavioural therapy intervention
Description: This is an oral 5mg psilocybin dose preceding a mental imagery rescripting procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with cognitive behavioural therapy intervention
Description: This is an oral placebo comparator preceding a mental imagery rescripting procedure
Study: NCT06799546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 tablets
Description: 200mg QD for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab Injection
Description: Eculizumab Injection for 24 weeks
Study: NCT06799910

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous renal replacement therapy (CRRT)
Description: The patient is included in the study once they meet the eligibility criteria and as soon as the responsible physician has prescribed RRT according to the department's protocol. Randomization will be performed, and the patient will be assigned to either the standard or experimental groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free UF Prescription
Description: The UF (ml/h) is prescribed by the responsible physician based on the patient's clinical, congestive, and hemodynamic status. The physician can implement the UF whenever necessary based on the patient's hemodynamic condition.
Study: NCT06799312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ipsilesional high frequency rTMS combined with physiotherapy
Description: As mentioned in details in arms description.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contralesional Continuous Burst Theta rTMS (cTBS) + Physiotherapy
Description: As mentioned in details in arms description.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS + Physiotherapy
Description: As mentioned in details in arms description.
Study: NCT06799975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients in the education group will have a meeting with a physiotherapist at the end of the T1 evaluation, which will take place in a suitable room that ensures privacy is maintained. During this meeting, the physiotherapist will provide the patient with advice regarding their return home and will suggest simple exercises to activate/maintain the abdominal and lower back muscles, to be performed at home until the next visit, one month after the surgery. These exercises are part of standard clinical practice and should be routinely performed by patients who undergo lumbar spinal fusion in the period following the surgery. Additionally, the patient will have the opportunity to communicate, via email or phone, with the physiotherapist until the follow-up appointment with the spine surgeon (scheduled for one month later).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual discharge procedures consist of a brief interview with the neurosurgeon during which instructions are provided on how to manage the first month after the surgery.
Study: NCT06799000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib Dose A
Description: Remibrutinib Dose A (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remibrutinib Dose B
Description: Remibrutinib Dose B (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib Dose B
Description: Remibrutinib Dose B (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo matching to remibrutinib Dose A (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Placebo matching to remibrutinib Dose B (oral)
Study: NCT06799832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urethal perfusion index monitoring
Description: The urethral perfusion index will be monitored using the IKORUS System (Vygon, Écouen, France)
Study: NCT06798532

Intervention type: OTHER
Intervention: Collection of data from the patient's medical file.
Description: Collection of data from the patient's medical file.
Study: NCT06799650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gammora®
Description: Gammora® SC + Tenofovir/3TC + darunavir+ritonavir
Study: NCT06799208

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Minimal invasive approach. Have peritoneal tissue sparing character . Minimal blood loss . Reduction of postoperative adhesions.
Study: NCT06798623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stromal Cells
Description: Autologous mesenchymal stromal/stem cells extracted from the subject during a routine standard of care ACL reconstruction surgery and reintroduced in one clinic visit approximately 21 days after completion of the surgery. After being removed from the patient, the cells will be cultured, modified, and harvested to become the final investigational product. Each subject will receive 1.5 ml of the investigative drug. This will contain 5x10\^7 (50 million) autologous MSCs.
Study: NCT06799637

Intervention type: DRUG
Group type: OTHER
Intervention: XNW28012
Description: Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.
Study: NCT06793215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered via IV infusion Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered via IV infusion Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered via IV infusion Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered via IV infusion Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered via IV infusion Q3W
Study: NCT06798415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia will be added. The solutions will be injected intralesionally and not subcutaneously.
Study: NCT06800209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain reprocessing therapy (PRT)
Description: A promising new psychotherapy for chronic pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be asked to continue to do whatever they are currently doing to manage their pain.
Study: NCT06798285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy Standard
Description: Group I: PPV with endoillumination set at 3.2 Lm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy 3D
Description: Group II: PPV with endoillumination set at 0.5 Lm.
Study: NCT06798038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: 35 Patients will be undergo for radiofrequency ablation which will be applied to each genicular nerve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenol neurolysis
Description: 35 Patients will be administered with 2.0 ml of 6% phenol solution prepared from crystallized phenol per genicular nerve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol neurolysis
Description: 35 Patients will be administered with 1.0ml of 70% alcohol per genicular nerve
Study: NCT06170385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
Study: NCT06798402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYO9867)
Description: Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium stibogluconate (Pentostam)
Description: Intralesional sodium stibogluconate (100 mg/ml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg/cm2)
Study: NCT06799390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagal nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Vagus nerve Stimulation
Description: Transcutaneous auricular vagal nerve ear clip applied without current
Study: NCT06799884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol / Levonorgestrel Oral Tablet
Description: Coated tablet of 20 µg ethinyl estradiol and 100 µg levonorgestrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol / Levonorgestrel Oral Tablet
Description: Coated tablet of 20 µg ethinyl estradiol and 100 µg levonorgestrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Film-coated tablet of aprocitentan 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Film-coated tablet of aprocitentan 25 mg
Study: NCT06799364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28-days consumption of Product A in 45 to 60-year-old healthy subjects.
Description: 40 healthy volunteers will consume Product A twice per day during 28 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28-days consumption of Product B in 45 to 60-year-old healthy subjects.
Description: 40 healthy volunteers will consume Product B twice per day during 28 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 28-days consumption of Control product in 45 to 60-year-old healthy subjects.
Description: 40 healthy volunteers will consume Control product twice per day during 28 consecutive days.
Study: NCT06800079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBT
Description: Elastic Band Resistance Training
Study: NCT06799715

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 33.5g sucrose dissolved in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 33.5g glucose dissolved in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: 33.5g fructose dissolved in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300mL water